Need, Development and Application of Virosomal System in Medicine
DOI:
https://doi.org/10.37285/ijpsn.2010.3.3.4Abstract
Virosomes are spherical, unilamellar phospholipid bilayer vesicle with a mean diameter is in range of 120-180 nm. Virosomes represent reconstituted empty influenza virus envelopes, which contain 70% phosphatidylcholine and remaining 30% neuraminidase (NA) and haemagglutinin (HA) glycoproteins. Various techniques are use for the loading the drug, protein and peptide like package inside the IRIV (immunopotentiatin reconstituted influenza virosome), intrigrated into lipid bilayer, anchored into lipid bilayer, crosslinked with HA (Hemaglutinin), and adsorbed to the membrane. Various protein, peptide, and malarial drugs are loaded in virus to deliver at particular site to give the targeted drug delivery. Virosomes could also be exploited as carriers for targeted drugs and for immunomodulating molecules particularly in cancer therapy. All these features allow us to consider influenza virosomes as a promising model for antigen and/or unrelated molecules delivery, which could be helpful for the development of new vaccines or immunotherapy protocols that combine safety with immunogenicity and their applicability in different field of medical research.
Downloads
Metrics
Keywords:
Virosomes, Influenza virus envelope, Malaria and Cancer treatment, Gene delivery
Downloads
Published
How to Cite
Issue
Section
References
Arkema A, Huckriede A, Schoen P, Wilschut J, Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide containing virosomes. Vaccine, 2000; 18:1327-33.
Bron R, Ortiz A, Dijkstra J, Stegmann T, Wilschut J. Preparation, properties, and applications of reconstituted influenza envelopes (virosomes). Methods in Enzimol., 1993; 220:313-31.
Cusi MG, Del Vecchio MT, Terrosi C, Gori Savellini G, Di Genova G, La Placa M, Fallarino F, Correale P. Immune-Reconstituted Influenza Virosome (IRIV) containing CD40L gene enhances the immunological and protective activity of a CEA anti-cancer vaccine. J. Immunol., 2005; 174:7210-6.
Cusi MG, Zurbriggen R, Valassina M, Bianchi S, Durrer P, Valensin PE, Donati M, Glück R. Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. Virology, 2000;277:111-8.
Daemen T, De Mare A, Bungener L, De Jonge J, Huckriede A, Wilschut J. Virosomes for antigen and DNA delivery. Adv. Drug Deliv. Rev., 2005; 57:451-63.
De Jonge J, Holtrop M, Wilschut J, Huckriede A. Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther., 2005; In press.
Dijkstra, J, Bron, R, Wilschut, J, de Haan, A,and Ryan, J.L. Activation of murine lymphocytes by lipopolysaccharide incorporated in fusogenic, reconstituted influenza virus envelopes (virosomes). J. Immunol., 1996; 157(3): 1028-1036.
Durrer P, Glück R, Spyr C, Lang AB, Zurbriggen R, Herzog R, Glück R. Mucosal antibody response induced with a nasal virosome-based influenza vacine. Vaccine, 2003;21:4238-4.
Glück R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz Jr SJ. Immunopotentiating reconstituted influenza virus virosome vaccine system for immunization against hepatitis A. J. Clin. Invest.,1992; 90:2491-5.
Huckriede A, Bungener L, Ter Veer W, Holtrop M, Daemen T, Palache AM, Wilschut J. Influenza virosomes: Combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine, 2003; 21:925-93.
Hunziker I, Zurbriggen R, Glück R, Engler OB, Reichen J, Dai WJ, Pichler WJ, Cerny A. Perspectives: Towards a peptide-based vaccine against hepatitis C virus. Mol. Immunol., 2001; 38:475-84.
Isabelle P, Hunziker Benno. In-vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus. International Immunology, 2002; 14(6): 615-626.
Loutan L, Bovier P, Althaus B, Glück R. Inactivated virosome hepatitis A vaccine. Lancet 1999; 343:322-4. Cusi MG,
Mastrobattista E, Schoen P, Wilschut J, Cromellin DJ, Storm G. Targeting influenza virosomes to ovarian carcinoma cells. FEBS Letters, 2001; 509:71-6.
Moser C, Metcalfe IC, Vitret JF. Virosomal adjuvanted antigen delivery system. Expert Rev. Vaccines, 2003; 2:89-96.
Mueller M, Renard A, Boato F, Vogel D, Naegeli M, Zurbriggen R, Robinson JA, Pluschke G. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen1. Infec. Immun., 2003; 71:4749-58.
Pöltl-Frank R, Zurbriggen R, Helg A, Stuart F, Robinson J, Glück R, Pluschke G. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Clin. Exp. Immunol., 1999; 117:496-503.
Poovorawan Y, Theamboonlers A, Chumdermpadetsuk S, Glück R, Cryz Jr SJ. Safety, immunogenicity, and kinetics of the immune response to a sigle dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine, 1995; 13:891-3.
Rock KL, York LA, Saric T, Goldberg AL. Protein degradation and the generation of MHC class-I presented peptides. Adv. Immunol., 2002;80:1-59.
Scardino A, Correale P, Firat H, et al. In vivo study of the GC/90IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse. Br. J. Cancer, 2003; 89:199-205.
Schoen P, and Chonn A, Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles. Gene Ther., 1999; 6(5): 823-832.
Stegmann T, Morselt HW, Booy FP, Van Breemen JF, Scherphof G, Wilschut J. Functional reconstitution of influenza virus envelopes. EMBO. J., 1987;6:899-901.
Waelti E, Wegmann N, Schwaninger R, Wetterwald A, Wingenfeld C, Rothen-Rutishauser B, Gimmi CD. Targeting HER/neu with antirat Neu virosomes for cancer therapy. Cancer Res., 2002; 62:437-44.
Waelti ER, Glück R. Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int. J. Cancer, 1998; 77:728-33.
Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science, 2001; 293:251-3.
Zurbriggen R, Amacker M, Kammer AR, Westerfeld N, Borghgraef P, Van Leuven F, Van der Auwera I, Wera S. Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer’s disease. J. Mol. Neurosci., 2005; 27:157-66.
Zurbriggen R, Correale P, Valassina M, Terrosi C, Pergola L, Valensin PE, Glück R. Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity. Vaccine, 2002; 20:3436-42.
